NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...

announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...

WASHINGTON - Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate-cancer drug Provenge, an innovative therapy that typically gives men suffering from an ...

WASHINGTON - A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval Thursday, offering an important alternative to more taxing ...

LUBBOCK, TX (KCBD) – The Food and Drug Administration has approved a prostate cancer vaccine designed to attack the disease using a man's own immune system. The vaccine, called Provenge, combines a ...

Dendreon filed for bankruptcy protection on Monday after sales of Provenge fell way short of expectations and the company could not pay off a huge debt coming due. By Andrew Pollack Costly treatments ...

Almost exactly a year after Dendreon Corp. set the prostate cancer space abuzz with the approval of immunotherapy Provenge (sipuleucel-T), Centocor Ortho Biotech Inc. scored another win with an FDA ...

LOS ANGELES (Reuters) - Men in the U.S. Medicare health insurance program will get full coverage of Dendreon Corp's prostate cancer therapy under a proposed payment decision by U.S. regulators ...